BarbaraSCraftMD

Oncology • Jackson, MS

Assistant Professor, Medicine, University of Mississippi School of Medicine

Join to view full profile

Dr. Craft is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Craft's full profile

Already have an account?

Office
2500 North State Street
Division Of Oncology
Jackson, MS 39216
Phone+1 601-984-5590

Fax+1 601-984-5599
Is this information wrong?

Education & Training

University of Mississippi Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
University of Mississippi Medical CenterResidency, Internal Medicine, 2001 - 2004
University of Mississippi School of MedicineClass of 2001

Certifications & Licensure

MS State Medical License 2003 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Start of enrollment: 2010 Apr 01
Completed
Phase 2
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
The Will Rogers phenomenon, Breast Cancer and Race
Mary R Nittala, Eswar K. Mundra, Satyaseelan Packianathan, Divyang Mehta, Maria L. Smith, William C. Woods, Shawn McKinney, Barbara S. Craft, Srinivasan Vijayakumar> ;BMC Cancer. 2021 May 17
3 citations
Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer.
Shou-Ching Tang, Carter Louis Capra, Germame Ajebo, Judith Meza-Junco, Simon Mairs, Barbara S. Craft, Xiaofu Zhu, Nita J. Maihle, William B. Hillegass> ;International Journal of Cancer. 2021 Apr 12
1 citations
A Partnership in Health-Related Social Media for Young Breast Cancer Survivors.
Donna L. Williams, Timiya S. Nolan, Yu-Wen Chiu, Laura Ricks, Silvia Gisiger Camata, Barbara S. Craft, Karen Meneses> ;Health Promotion Practice. 2020 Mar 1
39 citations
Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis
Ahmed A. Ejaeidi, Barbara S. Craft, Louis V. Puneky, Robert E. Lewis, Julius M. Cruse> ;Experimental and Molecular Pathology. 2015 Aug 1
1 citations
Plasma-cell mastitis with two other concomitant diseases.
Jeb S. Clark, Elizabeth Bui, Joshua C.M. Williams, Barbara S. Craft> ;The American Journal of Medicine. 2015 Aug 1
29 citations
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Zannel Blanchard, Bibbin T. Paul, Barbara S. Craft, Wael M. ElShamy> ;Breast Cancer Research. 2015 Jan 13
30 citations
Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells.
Taryn L. Green, Mark F. Santos, Ahmed A. Ejaeidi, Barbara S. Craft, Robert E. Lewis, Julius M. Cruse> ;Experimental and Molecular Pathology. 2014 Aug 1
39 citations
Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells
Mark F. Santos, Venkat K.R. Mannam, Barbara S. Craft, Louis V. Puneky, Natale T. Sheehan, Robert E. Lewis, Julius M. Cruse> ;Experimental and Molecular Pathology. 2014 Jun 1
29 citations
Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment.
Taryn L. Green, Julius M. Cruse, Robert E. Lewis, Barbara S. Craft> ;Experimental and Molecular Pathology. 2013 Oct 1
26 citations
Surveillance and monitoring of adult cancer survivors.
Minsig Choi, Barbara S. Craft, Stephen A. Geraci> ;The American Journal of Medicine. 2011 Jul 1
15 citations
The Changing Face of Phase 1 Cancer Clinical Trials : New Challenges in Study Requirements
Barbara S. Craft, Razelle Kurzrock, Xiudong Lei, Roy S. Herbst, Scott M. Lippman, Siqing Fu, Daniel D. Karp> ;Cancer. 2009 Apr 15
3 citations
Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer.
Stacy L. Moulder, Barbara S. Craft, Gabriel N. Hortobagyi> ;Anti-Cancer Agents in Medicinal Chemistry. 2008 May 31
2 citations
Adjuvant biologic therapy for breast cancer
Barbara S. Craft, Gabriel N. Hortobagyi, Stacy L. Moulder> ;Cancer Journal. 2007 May 1
Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test.
Harkin, A. J., Bruce, K. H., Craft, B., Paul, I. A.> ;Eur J Pharmacol. 1999 May 21
Join now to see all

Press Mentions

University of Mississippi Medical Center Earns American College of Radiology Breast Imaging Center of Excellence HonorsOctober 26th, 2021
MORE FUNDING, MORE OPTIONS — More Than 322,000 Breast Cancer Deaths Averted Between 1989 and 2015October 26th, 2017

Hospital Affiliations

University of Mississippi Medical CenterJackson, Mississippi

BarbaraSCraftMD

Dr. Craft is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.